Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance

An update from Amplia Therapeutics ( (AU:ATX) ) is now available.

Amplia Therapeutics has issued 240,385 fully paid ordinary shares following the exercise of Zero Exercise Price Options granted to its Chief Medical Officer under the company’s Equity Incentive Plan. The new shares rank equally with existing stock and were issued without a separate disclosure document under Australia’s Corporations Act, with the company confirming ongoing compliance with its financial reporting and continuous disclosure obligations and stating there is no undisclosed price-sensitive information, offering reassurance to investors about governance and transparency.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics is an Australian pharmaceutical company developing a pipeline of Focal Adhesion Kinase inhibitors targeting cancer and fibrosis. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis, positioning itself in a niche of targeted oncology and fibrosis therapeutics.

Average Trading Volume: 4,616,710

Technical Sentiment Signal: Hold

Current Market Cap: A$66.7M

Learn more about ATX stock on TipRanks’ Stock Analysis page.